🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🥁 A warm welcome to #ACC24 from the Shockwave Percussion ensemble! ⁦American College of Cardiology⁩ ⁦Healio⁩

Our team is caffeinated and ready for the next round of #ACC24 late-breaking clinical trials

Monthly #olezarsen reduced #triglyceride levels vs. placebo among patients with predominantly moderate hypertriglyceridemia and elevated CV risk Brian Bergmark Dan Soffer American College of Cardiology #Cardiotwitter #ACC24 Endocrine Today Healio Read more👇 healio.com/news/cardiolog…

Adults with obesity, #HFpEF and type 2 diabetes saw improvements in HF symptoms and physical function with #semaglutide 2.4 mg vs. placebo, despite less than typical weight loss Mikhail Kosiborod Saint Luke's Mid America Heart Institute Endocrine Today American College of Cardiology #ACC24 Read more👇 healio.com/news/cardiolog…

In the TACT2 trial, chelation therapy reduced levels of lead in the blood but did not improve cardiovascular outcomes for adults with diabetes and a prior heart attack #ACC24 @accintouch @accmediacenter Gervasio Lamas MD #cardiotwitter Read more👇 healio.com/news/cardiolog…

The Monday morning late-breakers at #ACC24 are kicking off. Check back for news from: 📌TACTiC 📌ARISE-HF 📌IMPROVE-HCM 📌DEPOSITION 📌PROACT

A screening study presented at #ACC24 showed that there is a high prevalence of unrecognized heart disease among former #NFL players American College of Cardiology #Cardiotwitter Healio #SportsCardiology Read more👇 healio.com/news/cardiolog…

New results from the TACTiC trial show the promise of technology to help individuals appropriately determine if they qualify for #statintherapy without a prescription Cleveland Clinic MD American College of Cardiology #ACC24 #Cardiotwitter Endocrine Today Healio Read more👇 healio.com/news/cardiolog…

🫀And, that’s a wrap for the Healio team at #AHA24! We had a blast in Chicago! ✈️ We ‘re heading home but our coverage continues. Keep 👀 out for news & expert perspectives from all the sessions! 📰 Catch up on all our coverage ⬇️ healio.com/news/cardiolog… American Heart Association

The challenges of #heartdisease “demand unwavering commitment” to innovation and progress, ACC President Cathleen Biga said American College of Cardiology ACC Media Center #ACC25

In the RIVAWAR trial, patients hospitalized for a heart attack who were treated with rivaroxaban for left ventricular thrombus had similar outcomes at 3 months to patients treated with warfarin #ACC25 @ACCMediaCenter American College of Cardiology healio.com/news/cardiolog…

From #ACC25: 📌 #Semaglutide improved walking distance at 1 year in people with diabetes and peripheral artery disease 📌 “We have …. a new drug for PAD,” presenter said here More on the STRIDE trial below

More from day 1 #ACC25: 📌 WARRIOR = the largest study of women with suspected ischemia with nonobstructive coronary disease 📌 Intensive medical therapy did not prevent 🫀 events for women with INOCA 📌 “This trial should not be considered a negative trial” Read more below

🔥Hot off the press: Highlights from day 1 at #ACC25 healio.com/news/cardiolog… 📌 WARRIOR: healio.com/news/cardiolog… 📌 STRIDE: healio.com/news/cardiolog… 📌 API-CAT: healio.com/news/cardiolog… 📌 SOUL: healio.com/news/cardiolog… 📌 RIVAWAR: healio.com/news/cardiolog… 📌 & more below

Is restricted fluid restriction or liberal fluid restriction better? New data from the FRESH-UP study ⬇️ #ACC25 #CardioTwitter

⏰ The *final* Late-Breaking Clinical Trial session is about to begin! 👀 for 🫀 TRILUMINATE 🫀 FAME 3 🫀 SMART CHOICE 🫀 ALLEPRE 🗞️ Stay tuned for coverage from Healio!

DapaTAVI at #ACC25: 📌 The SGLT2 inhibitor #dapagliflozin was safe and effective in older adults undergoing TAVR who were at high risk for #heartfailure 📌 Genital infections, hypotension more common 📌 A “practice-changing trial” Article below #CardioTwitter @DapaTAVI

New 5-year data from Evolut Low Risk Trial: 📌 At 5 years, no difference in death or disabling stroke between TAVR and surgery in patients at low surgical risk 📌 Both groups had improved QoL 📌 “These results are very encouraging for the TAVR population” More in link below

Positive data for lepodisiran presented at #ACC25: 📌 resulted in substantial reductions in lipoprotein(a) at 6 months and 1 year vs placebo in phase 2 study 📌 drug will allow infrequent administration 📌 a cardiovascular outcomes trial is underway More in the link below

🔥Highlights from day 2 #ACC25 All Healio Cardiology Today coverage here: healio.com/news/cardiolog… 📌 ALPACA: healio.com/news/cardiolog… 📌 BHF PROTECT-TAVI: healio.com/news/cardiolog… 📌 FRESH-UP: healio.com/news/cardiolog… 📌 Evolut Low Risk at 5 years, DapaTAVI & more below